CASI Pharmaceuticals, Inc. (CASI) Trading -5.9% Higher
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) shares were up 5.9% during trading on Thursday . The company traded as high as $2.63 and last traded at $2.41. Approximately 320,279 shares were traded during mid-day trading, a decline of 82% from the average daily volume of 1,740,961 shares. The stock had previously closed at $2.56.
A number of research analysts recently commented on CASI shares. ValuEngine downgraded shares of CASI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, July 22nd. Maxim Group set a $4.00 price objective on shares of CASI Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of CASI Pharmaceuticals in a research note on Friday, September 8th.
CASI Pharmaceuticals (NASDAQ:CASI) last announced its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.01). equities analysts anticipate that CASI Pharmaceuticals, Inc. will post -0.15 earnings per share for the current fiscal year.
In related news, Director Wei-Wu He bought 315,327 shares of CASI Pharmaceuticals stock in a transaction dated Friday, September 15th. The shares were acquired at an average cost of $1.33 per share, with a total value of $419,384.91. Following the completion of the transaction, the director now owns 212,323 shares in the company, valued at approximately $282,389.59. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders have bought 996,329 shares of company stock worth $1,647,138. Corporate insiders own 13.01% of the company’s stock.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.